Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

Publisher： Karger

E-ISSN： 1423-0232|93|3|164-176

ISSN： 0030-2414

Source： Oncology, Vol.93, Iss.3, 2017-06, pp. : 164-176

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3826-3835

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 297-305

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3821-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite

High‐sensitivity C‐reactive protein, low‐density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 654-659

John Wiley & Sons Inc

Access to resources Recommend Favorite